EP Patent

EP3873463A1 — Crystalline salts of a plasma kallikrein inhibitor

Assigned to Biocryst Pharmaceuticals Inc · Expires 2021-09-08 · 5y expired

What this patent protects

Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

USPTO Abstract

Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Drugs covered by this patent

Patent Metadata

Patent number: EP3873463A1
Jurisdiction: EP
Classification: —
Expires: 2021-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Biocryst Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.